Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.20
Bid: 13.10
Ask: 13.30
Change: 0.00 (0.00%)
Spread: 0.20 (1.527%)
Open: 13.25
High: 13.40
Low: 13.20
Prev. Close: 13.20
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avation loss narrows; Franchise Brands profit rises

Thu, 03rd Mar 2022 19:32

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Avation PLC - Singapore-based commercial passenger aircraft leasing company - For the six months ended December 31, pretax loss narrows to USD15.9 million from USD60.5 million, due to a much lower impairment loss on aircraft and credit losses. Revenue drops 6% year-on-year to USD57.9 million from USD61.3 million. Avation's aircraft fleet stands at 42, however fleet assets declines 7.0% year-on-year to USD1.00 billion as at December 31 from USD1.08 billion at the end of June.

----------

Franchise Brands PLC - Manchester-based owner of ChipsAway, Willow Pumps and Metro Rod brands - For 2021, pretax profit rises 57% year-on-year to GBP5.8 million from GBP3.7 million the year before, on revenue which grows 17% year-on-year to GBP57.7 million from GBP49.3 million, with double digit sales from Metro Rod and Metro Plumb, as well as a strong recovery from the B2C division. Declares final dividend of 0.9 pence per share, bringing total payout to 1.5p, up 36% from 1.1p. Looking ahead, reports strong start to 2022, with continued sales growth in B2B.

----------

Poolbeg Pharma PLC - London-based pharmaceutical company - For the period from incorporation on March 19 to December 31, posts pretax loss of GBP2.3 million and no revenue as the company continues to develop its severe influenza treatment POLB 001.

----------

Crystal Amber Fund Ltd - Guernsey-based investment company - As at December 31, net asset value per share increases 11% year-on-year to 143.19 pence from 128.99p. For the six month period, delivered NAV negative return of 0.8%, compared to a 4.7% positive return from the Numis Small Cap Index.

----------

JPMorgan Global Growth & Income PLC - invests in companies around the world - As at December 31, net asset value per share increases 6.1% year-on-year to 459.1 pence from 432.3p, while for the six month period, NAV total return is 8.2%, compared to a 7.7% return from the MSCI AC World Index.

----------

t42 IoT Tracking Solutions PLC - Jersey-based provider of tracking, security and monitoring solutions for containers and freight - For 2021, operating loss widens to USD2.7 million from USD1.8 million, on revenue which declines 16% year-on-year to USD4.2 million from USD5.0 million due to supply chain issues and a performance turnaround only taking place near the end of 2021.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - For the six months ended December 31, pretax profit drops 54% to GBP7.3 million from GBP15.8 million a year before, due to a rise in costs and a 10% year-on-year decline in revenue to GBP48.7 million from GBP54.0 million, due to the strategic streamlining of older products. Looking ahead, company has a strong outlook for the full financial year with operating profit on track to meet consensus expectations.

----------

Power Metal Resources PLC - London-based metals exploration company focused in North America, Africa and Australia - For the year ended September 30, pretax loss narrows to GBP623,000 from GBP1.4 million the year before, due to smaller impairment charges, and a slight rise in revenue to GBP37,000 from GBP9,000

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.